- 专利标题： Optimized anti-TL1A antibodies
-
申请号： US16863971申请日： 2020-04-30
-
公开(公告)号： US11440954B2公开(公告)日： 2022-09-13
- 发明人: Jeffry D. Watkins , Cindy T. Dickerson , J. Monty Watkins , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
- 申请人： Prometheus Biosciences, Inc. , Cedars-Sinai Medical Center
- 申请人地址： US CA San Diego; US CA Los Angeles
- 专利权人： Prometheus Biosciences, Inc.,Cedars-Sinai Medical Center
- 当前专利权人： Prometheus Biosciences, Inc.,Cedars-Sinai Medical Center
- 当前专利权人地址： US CA San Diego; US CA Los Angeles
- 代理机构： Wilson Sonsini Goodrich & Rosati
- 主分类号： C07K16/24
- IPC分类号： C07K16/24 ; C07K16/28 ; C12N5/10 ; C12N15/09 ; C12N15/63 ; A61P1/04 ; A61P1/00 ; A61K9/00 ; C07K14/525 ; C07K14/715 ; A61K39/395 ; A61K39/00
摘要：
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
公开/授权文献
- US20200255510A1 OPTIMIZED ANTI-TL1A ANTIBODIES 公开/授权日：2020-08-13
信息查询
